Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

380 ARTÍCULOS , VIENDO DEL 211 AL 225

Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis

Cao B, Rosenblat JD, Brietzke E, Park C, Lee Y, Musial N, Pan Z, Mansur RB, McIntyre RS.

Diabetes Obes Metab. 2018 Oct;20(10):2467-2471. doi: 10.1111/dom.13373. Epub 2018 Jun 19.

Role of p38/MAPKs in Alzheimer's disease: implications for amyloid beta toxicity targeted therapy

Kheiri G, Dolatshahi M, Rahmani F, Rezaei N.

Rev Neurosci. 2018 Dec 19;30(1):9-30. doi: 10.1515/revneuro-2018-0008.

Apelin, a promising target for Alzheimer disease prevention and treatment

Masoumi J, Abbasloui M, Parvan R, Mohammadnejad D, Pavon-Djavid G, Barzegari A, Abdolalizadeh J.

Neuropeptides. 2018 Aug;70:76-86. doi: 10.1016/j.npep.2018.05.008. Epub 2018 May 23.

Computational modeling and biomarker studies of pharmacological treatment of Alzheimer's disease (Review)

Hassan M, Abbas Q, Seo SY, Shahzadi S, Al Ashwal H, Zaki N, Iqbal Z, Moustafa AA.

Mol Med Rep. 2018 Jul;18(1):639-655. doi: 10.3892/mmr.2018.9044. Epub 2018 May 22.

The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update

Khoury R, Grysman N, Gold J, Patel K, Grossberg GT.

Expert Opin Investig Drugs. 2018 Jun;27(6):523-533. doi: 10.1080/13543784.2018.1483334. Epub 2018 Jun 18.

Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design

Devanand DP, Strickler JG, Huey ED, Crocco E, Forester BP, Husain MM, Vahia IV, Andrews H, Wall MM, Pelton GH.

Contemp Clin Trials. 2018 Aug;71:33-39. doi: 10.1016/j.cct.2018.05.019. Epub 2018 May 31.

Machine Learning-based Virtual Screening and Its Applications to Alzheimer's Drug Discovery: A Review

Carpenter KA, Huang X.

Curr Pharm Des. 2018;24(28):3347-3358. doi: 10.2174/1381612824666180607124038.

Reactive Astrocytes as Drug Target in Alzheimer's Disease

Assefa BT, Gebre AK, Altaye BM.

Biomed Res Int. 2018 May 14;2018:4160247. doi: 10.1155/2018/4160247. eCollection 2018.

Multi-targetable chalcone analogs to treat deadly Alzheimer's disease: Current view and upcoming advice

Zhang X, Rakesh KP, Bukhari SNA, Balakrishna M, Manukumar HM, Qin HL.

Bioorg Chem. 2018 Oct;80:86-93. doi: 10.1016/j.bioorg.2018.06.009. Epub 2018 Jun 5.

Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors

Giacobini E, Pepeu G.

Curr Alzheimer Res. 2018;15(11):1077-1084. doi: 10.2174/1567205015666180613111504.

Strategies for Continued Successful Treatment in Patients with Alzheimer's Disease: An Overview of Switching Between Pharmacological Agents

Blesa R, Toriyama K, Ueda K, Knox S, Grossberg G.

Curr Alzheimer Res. 2018;15(10):964-974. doi: 10.2174/1567205015666180613112040.

Tau-targeting therapies for Alzheimer disease

Congdon EE, Sigurdsson EM.

Nat Rev Neurol. 2018 Jul;14(7):399-415. doi: 10.1038/s41582-018-0013-z.

Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification

Hampel H, Vergallo A, Giorgi FS, Kim SH, Depypere H, Graziani M, Saidi A, Nisticò R, Lista S; Alzheimer Precision Medicine Initiative (APMI).

Front Neuroendocrinol. 2018 Jul;50:31-51. doi: 10.1016/j.yfrne.2018.06.001. Epub 2018 Jun 12.

Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study

Salloway SP, Sperling R, Fox NC, Sabbagh MN, Honig LS, Porsteinsson AP, Rofael H, Ketter N, Wang D, Liu E, Carr S, Black RS, Brashear HR.

J Alzheimers Dis. 2018;64(3):689-707. doi: 10.3233/JAD-171157.

Donepezil for dementia due to Alzheimer's disease

Birks JS, Harvey RJ.

Cochrane Database Syst Rev. 2018 Jun 18;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias